China's Biotechnology Success Meets Increasing US Scrutiny, Analytics Firm Says

MT Newswires Live07-29

China's rise as a global biotechnology innovation hub has worried the U.S., driving Washington to scrutinize the country's competitiveness and technological leadership rather than scientific advances alone, analytics firm GlobalData said in a Tuesday press release.

The implications of China's emergence extends "beyond healthcare innovation to include pharmaceutical supply-chain resilience, economic competitiveness, and national security," GlobalData healthcare analyst Edita Hamzic said.

GlobalData cited Akeso's (HKG:9926) presentation of its ivonescimab therapy at the American Society of Clinical Oncology as the first drug developed from a China-only clinical trial for non-small cell lung cancer patients as a display of China's scientific progress.

It also cited Wuxi AppTec's (HKG:2359, SHA:603259) inclusion in the U.S. Department of Defense's Section 1260H list of "Chinese military companies" that could affect its eligilibity for future U.S. governemnt contracts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655853679?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 12:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655853679","market":"nz","top_or_hot":-1,"title":"China's Biotechnology Success Meets Increasing US Scrutiny, Analytics Firm Says","media":"MT Newswires Live","content":"<html><body><p> China's rise as a global biotechnology innovation hub has worried the U.S., driving Washington to scrutinize the country's competitiveness and technological leadership rather than scientific advances alone, analytics firm GlobalData said in a Tuesday press release.</p><p>The implications of China's emergence extends \"beyond healthcare innovation to include pharmaceutical supply-chain resilience, economic competitiveness, and national security,\" GlobalData healthcare analyst Edita Hamzic said.</p><p>GlobalData cited Akeso's (HKG:9926) presentation of its ivonescimab therapy at the American Society of Clinical Oncology as the first drug developed from a China-only clinical trial for non-small cell lung cancer patients as a display of China's scientific progress.</p><p>It also cited Wuxi AppTec's (HKG:2359, SHA:603259) inclusion in the U.S. Department of Defense's Section 1260H list of \"Chinese military companies\" that could affect its eligilibity for future U.S. governemnt contracts.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Biotechnology Success Meets Increasing US Scrutiny, Analytics Firm Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Biotechnology Success Meets Increasing US Scrutiny, Analytics Firm Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-29 12:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China's rise as a global biotechnology innovation hub has worried the U.S., driving Washington to scrutinize the country's competitiveness and technological leadership rather than scientific advances alone, analytics firm GlobalData said in a Tuesday press release.</p><p>The implications of China's emergence extends \"beyond healthcare innovation to include pharmaceutical supply-chain resilience, economic competitiveness, and national security,\" GlobalData healthcare analyst Edita Hamzic said.</p><p>GlobalData cited Akeso's (HKG:9926) presentation of its ivonescimab therapy at the American Society of Clinical Oncology as the first drug developed from a China-only clinical trial for non-small cell lung cancer patients as a display of China's scientific progress.</p><p>It also cited Wuxi AppTec's (HKG:2359, SHA:603259) inclusion in the U.S. Department of Defense's Section 1260H list of \"Chinese military companies\" that could affect its eligilibity for future U.S. governemnt contracts.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0540923850.HKD","symbol_name":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2655853679","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655853679","pubTimestamp":1785298770,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's rise as a global biotechnology innovation hub has worried the U.S., driving Washington to scrutinize the country's competitiveness and technological leadership rather than scientific advances alone, analytics firm GlobalData said in a Tuesday press release.The implications of China's emergence extends \"beyond healthcare innovation to include pharmaceutical supply-chain resilience, economic competitiveness, and national security,\" GlobalData healthcare analyst Edita Hamzic said.GlobalData cited Akeso's  presentation of its ivonescimab therapy at the American Society of Clinical Oncology as the first drug developed from a China-only clinical trial for non-small cell lung cancer patients as a display of China's scientific progress.It also cited Wuxi AppTec's  inclusion in the U.S. Department of Defense's Section 1260H list of \"Chinese military companies\" that could affect its eligilibity for future U.S. governemnt contracts.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603259":"药明康德","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","BK1583":"高瓴概念","BK0216":"研究试验","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","LU0611395673.USD":"NINETY ONE GSF EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","09926":"康方生物","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","02359":"药明康德","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","BK1161":"生物科技","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD"},"translate_title":"分析公司表示，中国生物技术的成功面临美国越来越多的审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":0.9,"KURE":0.6,"02359":0.9,"09926":1},"content_text":"China's rise as a global biotechnology innovation hub has worried the U.S., driving Washington to scrutinize the country's competitiveness and technological leadership rather than scientific advances alone, analytics firm GlobalData said in a Tuesday press release.The implications of China's emergence extends \"beyond healthcare innovation to include pharmaceutical supply-chain resilience, economic competitiveness, and national security,\" GlobalData healthcare analyst Edita Hamzic said.GlobalData cited Akeso's (HKG:9926) presentation of its ivonescimab therapy at the American Society of Clinical Oncology as the first drug developed from a China-only clinical trial for non-small cell lung cancer patients as a display of China's scientific progress.It also cited Wuxi AppTec's (HKG:2359, SHA:603259) inclusion in the U.S. Department of Defense's Section 1260H list of \"Chinese military companies\" that could affect its eligilibity for future U.S. governemnt contracts.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655853679","isCrawlerRequest":true}